Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers.

Katisko K, Solje E, Koivisto AM, Krüger J, Kinnunen T, Hartikainen P, Helisalmi S, Korhonen V, Herukka SK, Haapasalo A, Remes AM.

J Neuroimmunol. 2018 Aug 15;321:29-35. doi: 10.1016/j.jneuroim.2018.05.011. Epub 2018 May 22.

PMID:
29957385
2.

How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?

Lehtola H, Hartikainen J, Hartikainen P, Kiviniemi T, Nuotio I, Palomäki A, Ylitalo A, Airaksinen KEJ, Mustonen P.

Clin Cardiol. 2018 May;41(5):608-614. doi: 10.1002/clc.22935. Epub 2018 May 10.

3.

Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis.

Cajanus A, Hall A, Koikkalainen J, Solje E, Tolonen A, Urhemaa T, Liu Y, Haanpää RM, Hartikainen P, Helisalmi S, Korhonen V, Rueckert D, Hasselbalch S, Waldemar G, Mecocci P, Vanninen R, van Gils M, Soininen H, Lötjönen J, Remes AM.

Dement Geriatr Cogn Dis Extra. 2018 Feb 23;8(1):51-59. doi: 10.1159/000486849. eCollection 2018 Jan-Apr.

4.

Usefulness of the CHA2DS2-VASc and HAS-BLED Scores in Predicting the Risk of Stroke Versus Intracranial Bleeding in Patients With Atrial Fibrillation (from the FibStroke Study).

Jaakkola S, Kiviniemi TO, Nuotio I, Hartikainen J, Mustonen P, Palomäki A, Jaakkola J, Ylitalo A, Hartikainen P, Airaksinen KEJ.

Am J Cardiol. 2018 May 15;121(10):1182-1186. doi: 10.1016/j.amjcard.2018.01.038. Epub 2018 Feb 12.

PMID:
29526276
5.

Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

Laiho A, Laitinen TM, Hartikainen P, Hartikainen JEK, Laitinen TP, Simula S.

Brain Behav. 2018 Jan 30;8(2):e00925. doi: 10.1002/brb3.925. eCollection 2018 Feb.

6.

Low Prevalence of Cancer in Patients with Frontotemporal Lobar Degeneration.

Katisko K, Haapasalo A, Koivisto A, Krüger J, Hartikainen P, Korhonen V, Helisalmi S, Herukka SK, Remes AM, Solje E.

J Alzheimers Dis. 2018;62(2):789-794. doi: 10.3233/JAD-170854.

PMID:
29480183
7.

Alpha-synucleinopathies.

Alafuzoff I, Hartikainen P.

Handb Clin Neurol. 2017;145:339-353. doi: 10.1016/B978-0-12-802395-2.00024-9. Review.

PMID:
28987181
8.

Neuropsychological Profile in the C9ORF72 Associated Behavioral Variant Frontotemporal Dementia.

Suhonen NM, Haanpää RM, Korhonen V, Jokelainen J, Pitkäniemi A, Heikkinen AL, Krüger J, Hartikainen P, Helisalmi S, Hiltunen M, Hänninen T, Remes AM.

J Alzheimers Dis. 2017;58(2):479-489. doi: 10.3233/JAD-161142.

PMID:
28453474
9.

Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk.

Lehtola H, Airaksinen KEJ, Hartikainen P, Hartikainen JEK, Palomäki A, Nuotio I, Ylitalo A, Kiviniemi T, Mustonen P.

Eur J Neurol. 2017 May;24(5):719-725. doi: 10.1111/ene.13280. Epub 2017 Mar 20.

PMID:
28317289
10.

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

Simula S, Laitinen TP, Laitinen TM, Hartikainen P, Hartikainen JEK.

Ann Noninvasive Electrocardiol. 2017 Sep;22(5). doi: 10.1111/anec.12443. Epub 2017 Feb 13.

PMID:
28191684
11.

Stroke as the First Manifestation of Atrial Fibrillation.

Jaakkola J, Mustonen P, Kiviniemi T, Hartikainen JE, Palomäki A, Hartikainen P, Nuotio I, Ylitalo A, Airaksinen KE.

PLoS One. 2016 Dec 9;11(12):e0168010. doi: 10.1371/journal.pone.0168010. eCollection 2016.

12.

Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.

Simula S, Laitinen TP, Laitinen TM, Hartikainen P, Hartikainen JE.

Mult Scler Relat Disord. 2016 Nov;10:86-89. doi: 10.1016/j.msard.2016.09.012. Epub 2016 Sep 30.

PMID:
27919506
13.

Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease.

Kokkonen N, Herukka SK, Huilaja L, Kokki M, Koivisto AM, Hartikainen P, Remes AM, Tasanen K.

J Invest Dermatol. 2017 Jan;137(1):71-76. doi: 10.1016/j.jid.2016.09.010. Epub 2016 Sep 17.

14.

Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease.

Muñoz-Ruiz MÁ, Hall A, Mattila J, Koikkalainen J, Herukka SK, Husso M, Hänninen T, Vanninen R, Liu Y, Hallikainen M, Lötjönen J, Remes AM, Alafuzoff I, Soininen H, Hartikainen P.

Dement Geriatr Cogn Dis Extra. 2016 Jul 22;6(2):313-329. eCollection 2016 May-Aug.

15.

Mortality after stroke in patients with paroxysmal and chronic atrial fibrillation - The FibStroke study.

Palomäki A, Kiviniemi T, Mustonen P, Odei C, Hartikainen JEK, Nuotio I, Ylitalo A, Hartikainen P, Biancari F, Airaksinen KEJ.

Int J Cardiol. 2017 Jan 15;227:869-874. doi: 10.1016/j.ijcard.2016.06.107. Epub 2016 Jun 23.

PMID:
27639597
16.

Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.

Simula S, Laitinen TP, Laitinen TM, Hartikainen P, Hartikainen JE.

Physiol Rep. 2016 Sep;4(17). pii: e12870. doi: 10.14814/phy2.12870.

17.

Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women.

Haapalinna F, Paajanen T, Penttinen J, Kokki H, Kokki M, Koivisto AM, Hartikainen P, Solje E, Hänninen T, Remes AM, Herukka SK.

Dement Geriatr Cogn Dis Extra. 2016 Jul 19;6(2):303-12. doi: 10.1159/000446425. eCollection 2016 May-Aug.

18.

Postoperative Strokes and Intracranial Bleeds in Patients With Atrial Fibrillation: The FibStroke Study.

Palomäki A, Kiviniemi T, Hartikainen JE, Mustonen P, Ylitalo A, Nuotio I, Hartikainen P, Jaakkola J, Luite R, Airaksinen KE.

Clin Cardiol. 2016 Aug;39(8):471-6. doi: 10.1002/clc.22554. Epub 2016 May 30.

19.

Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion.

Junttila A, Kuvaja M, Hartikainen P, Siloaho M, Helisalmi S, Moilanen V, Kiviharju A, Jansson L, Tienari PJ, Remes AM, Herukka SK.

Dement Geriatr Cogn Dis Extra. 2016 Apr 16;6(1):142-9. doi: 10.1159/000444788. eCollection 2016 Jan-Apr.

20.

Strokes after cardioversion of atrial fibrillation--The FibStroke study.

Palomäki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, Hartikainen P, Lehtola H, Luite R, Airaksinen KE.

Int J Cardiol. 2016 Jan 15;203:269-73. doi: 10.1016/j.ijcard.2015.10.168. Epub 2015 Oct 20.

PMID:
26519683
21.

Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.

Simula S, Laitinen T, Laitinen TM, Tarkiainen T, Hartikainen P, Hartikainen JE.

Mult Scler. 2016 Jul;22(8):1080-5. doi: 10.1177/1352458515604384. Epub 2015 Sep 11.

PMID:
26362903
22.

Underuse of anticoagulation in stroke patients with atrial fibrillation--the FibStroke Study.

Palomäki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, Hartikainen P, Airaksinen KE.

Eur J Neurol. 2016 Jan;23(1):133-9. doi: 10.1111/ene.12820. Epub 2015 Aug 11.

PMID:
26263442
23.

[Update on Current Care Guideline: Multiple sclerosis].

Remes A, Airas L, Atula S, Färkkilä M, Hartikainen P, Koivisto K, Mäenpää E, Ruutiainen J, Sumelahti ML; Päivitystiivistelmä.

Duodecim. 2015;131(5):500-1. Finnish.

PMID:
26237913
24.

The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD.

Solje E, Aaltokallio H, Koivumaa-Honkanen H, Suhonen NM, Moilanen V, Kiviharju A, Traynor B, Tienari PJ, Hartikainen P, Remes AM.

PLoS One. 2015 Jul 6;10(7):e0131817. doi: 10.1371/journal.pone.0131817. eCollection 2015.

25.

Effects of Three Months Fingolimod Therapy on Heart Rate.

Simula S, Laitinen T, Laitinen TM, Tarkiainen T, Hartikainen JE, Hartikainen P.

J Neuroimmune Pharmacol. 2015 Dec;10(4):651-4. doi: 10.1007/s11481-015-9619-8. Epub 2015 Jun 20.

PMID:
26092537
26.

The CERAD Neuropsychological Battery in Patients with Frontotemporal Lobar Degeneration.

Haanpää RM, Suhonen NM, Hartikainen P, Koivisto AM, Moilanen V, Herukka SK, Hänninen T, Remes AM.

Dement Geriatr Cogn Dis Extra. 2015 Apr 14;5(1):147-54. doi: 10.1159/000380815. eCollection 2015 Jan-Apr.

27.

Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion.

Kämäläinen A, Herukka SK, Hartikainen P, Helisalmi S, Moilanen V, Knuuttila A, Jansson L, Tienari PJ, Remes AM.

Dement Geriatr Cogn Disord. 2015;39(5-6):287-93. doi: 10.1159/000371704. Epub 2015 Mar 13.

PMID:
25791939
28.

C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation.

Solje E, Hartikainen P, Valori M, Vanninen R, Tiihonen J, Hakola P, Tienari PJ, Remes AM.

Neurobiol Aging. 2014 Jul;35(7):1780.e13-7. doi: 10.1016/j.neurobiolaging.2014.01.149. Epub 2014 Feb 5.

PMID:
24612676
29.

TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.

Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, Frosch MP, Alafuzoff I, Antonell A, Bogdanovic N, Brooks W, Cairns NJ, Cooper-Knock J, Cotman C, Cras P, Cruts M, De Deyn PP, DeCarli C, Dobson-Stone C, Engelborghs S, Fox N, Galasko D, Gearing M, Gijselinck I, Grafman J, Hartikainen P, Hatanpaa KJ, Highley JR, Hodges J, Hulette C, Ince PG, Jin LW, Kirby J, Kofler J, Kril J, Kwok JB, Levey A, Lieberman A, Llado A, Martin JJ, Masliah E, McDermott CJ, McKee A, McLean C, Mead S, Miller CA, Miller J, Munoz DG, Murrell J, Paulson H, Piguet O, Rossor M, Sanchez-Valle R, Sano M, Schneider J, Silbert LC, Spina S, van der Zee J, Van Langenhove T, Warren J, Wharton SB, White CL 3rd, Woltjer RL, Trojanowski JQ, Lee VM, Van Deerlin V, Chen-Plotkin AS.

Acta Neuropathol. 2014 Mar;127(3):407-18. doi: 10.1007/s00401-013-1239-x. Epub 2014 Jan 19.

30.

Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment.

Muñoz-Ruiz MÁ, Hartikainen P, Hall A, Mattila J, Koikkalainen J, Herukka SK, Julkunen V, Vanninen R, Liu Y, Lötjönen J, Soininen H.

J Alzheimers Dis. 2013;35(4):727-39. doi: 10.3233/JAD-122260.

PMID:
23455991
31.

Structural MRI in frontotemporal dementia: comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry.

Muñoz-Ruiz MÁ, Hartikainen P, Koikkalainen J, Wolz R, Julkunen V, Niskanen E, Herukka SK, Kivipelto M, Vanninen R, Rueckert D, Liu Y, Lötjönen J, Soininen H.

PLoS One. 2012;7(12):e52531. doi: 10.1371/journal.pone.0052531. Epub 2012 Dec 20.

32.

Cortical thickness in frontotemporal dementia, mild cognitive impairment, and Alzheimer's disease.

Hartikainen P, Räsänen J, Julkunen V, Niskanen E, Hallikainen M, Kivipelto M, Vanninen R, Remes AM, Soininen H.

J Alzheimers Dis. 2012;30(4):857-74. doi: 10.3233/JAD-2012-112060.

PMID:
22466003
33.

Distribution and pattern of pathology in subjects with familial or sporadic late-onset cerebellar ataxia as assessed by p62/sequestosome immunohistochemistry.

Pikkarainen M, Hartikainen P, Soininen H, Alafuzoff I.

Cerebellum. 2011 Dec;10(4):720-31. doi: 10.1007/s12311-011-0281-2.

PMID:
21544590
34.

Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions.

Hartikainen PH, Pikkarainen M, Hänninen T, Soininen H, Alafuzoff I.

Neuropathology. 2012 Feb;32(1):60-8. doi: 10.1111/j.1440-1789.2011.01218.x. Epub 2011 Apr 26.

PMID:
21518013
35.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
36.

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL 3rd, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, Lopez de Munain A, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM.

Nat Genet. 2010 Mar;42(3):234-9. doi: 10.1038/ng.536. Epub 2010 Feb 14.

37.

Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43.

Pikkarainen M, Hartikainen P, Alafuzoff I.

Neuropathology. 2010 Apr;30(2):197-9. doi: 10.1111/j.1440-1789.2009.01043.x. Epub 2009 Jul 19. No abstract available.

PMID:
19622109
38.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
39.

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J.

Eur J Clin Pharmacol. 2009 May;65(5):443-55. doi: 10.1007/s00228-009-0622-y. Epub 2009 Feb 20.

PMID:
19229530
40.

Expression of collagen XVII and ubiquitin-binding protein p62 in motor neuron disease.

Seppänen A, Pikkarainen M, Hartikainen P, Hofmann SC, Majamaa K, Alafuzoff I.

Brain Res. 2009 Jan 9;1247:171-7. doi: 10.1016/j.brainres.2008.10.020. Epub 2008 Nov 1.

PMID:
18992722
41.

Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry.

Pikkarainen M, Hartikainen P, Alafuzoff I.

J Neuropathol Exp Neurol. 2008 Apr;67(4):280-98. doi: 10.1097/NEN.0b013e31816a1da2.

PMID:
18379439
42.

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms.

Parkkinen L, Hartikainen P, Alafuzoff I.

Clin Neuropathol. 2007 Nov-Dec;26(6):276-83.

PMID:
18232593
43.

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).

Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H.

Acta Neurol Scand. 2006 Sep;114(3):181-6.

PMID:
16911346
44.

Hippocampus and entorhinal cortex in mild cognitive impairment and early AD.

Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso MP, Hallikainen M, Vanhanen M, Nissinen A, Helkala EL, Vainio P, Vanninen R, Partanen K, Soininen H.

Neurobiol Aging. 2004 Mar;25(3):303-10.

PMID:
15123335
45.

Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia.

Autere J, Moilanen JS, Finnilä S, Soininen H, Mannermaa A, Hartikainen P, Hallikainen M, Majamaa K.

Hum Genet. 2004 Jun;115(1):29-35. Epub 2004 Apr 24.

PMID:
15108120
46.

Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland.

Autere JM, Hiltunen MJ, Mannermaa AJ, Jäkälä PA, Hartikainen PH, Majamaa K, Alafuzoff I, Soininen HS.

Eur J Neurol. 2002 Sep;9(5):479-83.

PMID:
12220378
47.

Increased risk of sensorineural hearing loss and migraine in patients with a rare mitochondrial DNA variant 4336A>G in tRNAGln.

Finnilä S, Autere J, Lehtovirta M, Hartikainen P, Mannermaa A, Soininen H, Majamaa K.

J Med Genet. 2001 Jun;38(6):400-5. No abstract available.

48.

Heterogeneity of cerebral blood flow: a fractal approach.

Kuikka JT, Hartikainen P.

Nuklearmedizin. 2000;39(2):37-42.

PMID:
10768168
49.

A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism.

Lehtovirta M, Partanen J, Könönen M, Hiltunen J, Helisalmi S, Hartikainen P, Riekkinen P Sr, Soininen H.

Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):29-35.

PMID:
10629359
50.

Rapidly progressive multifocal leukoencephalopathy with substantial cell-mediated inflammatory response and with cognitive decline of non-Alzheimer type in a 75-year-old female patient.

Alafuzoff I, Hartikainen P, Hanninen T, Partanen K, Kuikka J, Syrjänen K, Naukkarinen A, Soininen H.

Clin Neuropathol. 1999 May-Jun;18(3):113-23.

PMID:
10361995

Supplemental Content

Loading ...
Support Center